AIDES and PLUS announced to conference attendees from the world over results from the biggest European survey ever to be conducted regarding knowledge, interest and utilisation of PrEP, Flash! PrEP in Europe. This presentation revealed the principal barriers, both individual and structural, regarding access to this ...

PARIS — The last time the International AIDS Society Conference on HIV Science met in 2003, fewer than 2 million people globally were on HIV treatment. As the event returned to Paris this week, UNAIDS reported 19.5 million people are now taking antiretroviral therapy, or ART. The numbers put ...

In 2015, viral hepatitis caused the death of 1 million 340 thousand people around the world. Such data are published in the report of the World Health Organization, during the International Congress on diseases of the liver ILC 2017 held in Amsterdam. One of the causes of high mortality is the ...

Extension of 2013 agreement allows an additional 1.4 million people living with HIV to benefit from sublicensed generics of World Health Organization-recommended antiretroviral. Paris, 25 July 2017 — The Medicines Patent Pool (MPP) has signed an extension of its licensing agreement with biopharmaceutical company Bristol-Myers Squibb ...

AbbVie’s new pangenotypic regimen combining glecaprevir and pibrentasvir cured almost all HIV-positive people with hepatitis C co-infection in the EXPEDITION-2 study, according to a presentation on Monday at the 9th International AIDS Society Conference on HIV Science (IAS 2017) in Paris. Glecaprevir/pibrentasvir (Maviret) is expected to be approved ...

HVTN 705 vaccine study passes its “go” criteria: due to start this autumn A year ago, one of the biggest pieces of prevention news at the Durban International AIDS Conference was the announcement that a large HIV vaccine efficacy study would start in South Africa. HVTN 702, ...

The report published today focuses on the status of current, emerging and potential technologies in TB diagnosis. Many countries still rely on tools such as sputum-smear microscopy but new diagnostics are slowly changing the TB diagnostics landscape. Tuberculosis (TB) continues to be a major public health ...

23.07.2017 The results from clinical trials are usually discussed within the scientific community only and are seldom spread to the general public. With the release of the EU Clinical Trials Regulation 536/2014 in 2014, informing the public about clinical trial results will become mandatory in Europe. Lay ...

WHO today prequalified the first generic version of sofosbuvir, a critical medicine for the treatment of hepatitis C. The development could expand access to treatment by increasing the number of quality-assured generic medicines on the market. Sofosbuvir, 400 mg tablet, is manufactured by Mylan Laboratories ...

A new report released today ahead of the 9th IAS Conference on HIV Science documents 2016 funding and highlights a continuing trend of flat or declining funding and its potential impact on further innovation in HIV prevention research and development (R&D). The Resource Tracking for HIV Prevention ...

The objectives of these guidelines are to provide recommendations outlining a public health approach to managing people presenting with advanced HIV disease, and to provide guidance on the timing of initiation of antiretroviral therapy (ART) for all people living with HIV. The first set of recommendations ...

The latest progress report from UNAIDS shows significant strides towards achieving the 90-90-90 targets, with 70% of people living with HIV now aware of their HIV status. Of those who know their status 77% were accessing treatment, and 82% of those accessing treatment were virally ...

Ahead of next week’s International AIDS Society Conference on HIV Science in Paris, France, the Global Fund to Fight AIDS, Tuberculosis and Malaria today announced new results that highlight accelerating progress in providing HIV prevention, treatment and care services. The results show that 11 million people are receiving ...

Released in advance of the 9th IAS Conference on HIV Science convening next week in Paris, our 2017 report continues to demonstrate the significant yields of drugs and biologics research and the advancement of breakthrough technologies that aim to detect, prevent, treat or cure HIV, tuberculosis ...

Following the CCM TB/AIDS extraordinary meeting held on June 29, 2017 and the decisions adopted during the meeting, a group of 6 NGOs, CCM members, initiated an active campaign of: 1) contesting the CCM procedures, 3) unilateral misinformation of public opinion, the donor (GF), the development partners, and ...

This year i-Base has produced the HIV pipeline review as part of our Fit for Purpose report on HIV treatment optimisation. Two versions of the HIV pipeline are available: The full version reports key research in detail for each drug. Read the full pipeline report online. The new ...

A call for applications for the European HIV Academy for Enabling Legal Environments is now open. This two-day training academy for people living with and affected by HIV, is dedicated to skills building for addressing punitive or disabling legal environments. Around 25 participants from across Europe will ...

The incidence of hepatitis E virus (HEV) infection has been steadily increasing across the countries of the European Union and European Economic Area (EU/EEA) with 21 081 cases reported in the EU/EEA over the last decade. According to data published by ECDC, the number of confirmed ...